Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Victoria Barghout, MSPH

Articles by Victoria Barghout, MSPH

Tegaserod Treatment for IBS: A Model of Indirect Costs

ByDean G. Smith, PhD,Victoria Barghout, MSPH,Kristijan H. Kahler, SM

April 15th 2005

Effectiveness of Tegaserod Therapy on GI-related Resource Utilization in a Managed Care Population

ByJudith J. Stephenson, SM,Victoria Barghout, MSPH,Kristijan H. Kahler, SM,Joaquim Fernandes, BA,Jane F. Beaulieu, MSN,Samuel Joo, MS,Stephen J. Boccuzzi, PhD

April 15th 2005

Total Costs of IBS: Employer and Managed Care Perspective

ByBrooks Cash, MD, FACP,Sean Sullivan, JD,Victoria Barghout, MSPH

April 15th 2005

Budget Impact of Tegaserod on a Managed Care Organization Formulary

ByMichael A. Bloom, BA,Victoria Barghout, MSPH,Kristijan H. Kahler, SM,Judith Bentkover, PhD,Hannah Kurth, BA,Ian M. Gralnek, MD, MSHS,Brennan M. R. Spiegel, MD, MSHS

April 15th 2005

Impairment in Work Productivity and Health-related Quality of Life in Patients With IBS

ByBonnie B. Dean, PhD,Daniel Aguilar, MPH,Victoria Barghout, MSPH,Kristijan H. Kahler, SM,Feride Frech, MPH,David Groves, PhD,Joshua J. Ofman, MD

April 15th 2005

Latest Updated Articles

Tegaserod Treatment for IBS: A Model of Indirect Costs
April 15th 2005
Effectiveness of Tegaserod Therapy on GI-related Resource Utilization in a Managed Care Population
April 15th 2005
Total Costs of IBS: Employer and Managed Care Perspective
April 15th 2005
Budget Impact of Tegaserod on a Managed Care Organization Formulary
April 15th 2005
Impairment in Work Productivity and Health-related Quality of Life in Patients With IBS
April 15th 2005

Trending on AJMC

FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week

Trump Announces Timeline for 100% Generic Drug Tariffs Beginning in 2028, 200% in 2029

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Dermatology Practices Absorb Rising Prior Authorization Costs

Clesrovimab Demonstrates Safety Through a Second RSV Season in High-Risk Infants